Evidence map›Paper›PMID 33153192›Full record

ArticleDiagnostics (Basel, Switzerland)2020

Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients.

Elba Marin, Roxana Reyes, Ainara Arcocha, Nuria Viñolas, Laura Mezquita, Elena Gonzalvo, Karmele Saez de Gordoa, Pedro Jares, Noemi Reguart, Cristina Teixido

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Elba MarinDivision of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0001-8882-7552
Roxana ReyesDivision of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain.
Ainara ArcochaDivision of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain.
Nuria ViñolasDivision of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain.
Laura MezquitaDivision of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain.
Elena GonzalvoDivision of Pathology, Hospital Clínic, 08036 Barcelona, Spain.
Karmele Saez de GordoaDivision of Pathology, Hospital Clínic, 08036 Barcelona, Spain.ORCID 0000-0001-8106-6121
Pedro JaresUnitat funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain.
Noemi ReguartDivision of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain.
Cristina TeixidoTranslational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi I Sunyer, 08036 Barcelona, Spain.ORCID 0000-0002-7226-6567
Hospital Clínic de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted therapies are a new paradigm in lung cancer management. Next-generation sequencing (NGS) techniques have allowed for simultaneous testing of several genes in a rapid and efficient manner; however, there are other molecular diagnostic tools such as the nCounter

Indexed as

advanced non-small cell lung cancermolecular diagnosticsmutationsnCounternext-generation sequencing

Identifiers

PMID33153192
PMCPMC7693424
OpenAlexW3097413504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.